Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Dow
Moodys
Baxter
Medtronic

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for RECKITT BENCKISER INC. v. TRIS PHARMA, INC. (D.N.J. 2009)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

RECKITT BENCKISER INC. v. TRIS PHARMA, INC. (D.N.J. 2009)

Docket   Start Trial Date Filed 2009-06-26
Court District Court, D. New Jersey Date Terminated 2012-07-31
Cause 35:271 Patent Infringement Assigned To Magistrate Judge Douglas E. Ar
Jury Demand None Referred To
Parties RECKITT BENCKISER INC.; TRIS PHARMA, INC.; UCB MANUFACTURING, INC.; YU-HSING TU
Patents 4,221,778; 5,980,882
Attorneys CARISSA L. RODRIGUE; CHARLES A. WEISS; ELINA SLAVIN; JOHN EDMUND FLAHERTY; JONATHAN M.H. SHORT; MARK H. ANANIA; SYMONE J. REDWINE; WILLIAM J. HELLER
Firms Holland & Knight LLP; McCarter and English, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in RECKITT BENCKISER INC. v. TRIS PHARMA, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for RECKITT BENCKISER INC. v. TRIS PHARMA, INC. (D.N.J. 2009)

Date Filed Document No. Description Snippet Link To Document
2011-10-17 139 infringement of United States Letters Patent No. 5,980,882 (“‘882 patent”) which “claims certain pharmaceutical….C. § 355 (j) before the expiration of the ‘882 patent – specifically, seeking approval to engage in…will also infringe one or more claims of the ‘882 patent. Id. at 4. As a result, Plaintiffs claim that…earlier than after the expiration date of the ‘882 patent pursuant to 35 U.S.C. § 271(e)(4) and an award…respect to the subject matter claimed in the ‘882 patent. Id. at 5. Plaintiffs also claim that they are External link to document
2011-10-17 140 infringement of United States Letters Patent No. 5,980,882 (“‘882 patent”) which “claims certain pharmaceutical….C. § 355 (j) before the expiration of the ‘882 patent – specifically, seeking approval to engage in…will also infringe one or more claims of the ‘882 patent. Id. at 4. As a result, Plaintiffs claim that…earlier than after the expiration date of the ‘882 patent pursuant to 35 U.S.C. § 271(e)(4) and an award…respect to the subject matter claimed in the ‘882 patent. Id. at 5. Plaintiffs also claim that they are External link to document
2011-10-18 142 infringement of United States Letters Patent No. 5,980,882 (“‘882 patent”) which “claims certain pharmaceutical…”. Given that this is a patent case, the Court notes that the Local Patent Rules for the District of….C. § 355 (j) before the expiration of the ‘882 patent – specifically, seeking approval to engage in…will also infringe one or more claims of the ‘882 patent. Id. at 4. As a result, Plaintiffs claim that…earlier than after the expiration date of the ‘882 patent pursuant to 35 U.S.C. § 271(e)(4) and an award External link to document
2011-11-04 159 Claims 24 and 25 of US Patent No. 5,980,882 from the Complaint; the remaining patent claims and causes of…2009 31 July 2012 3:09-cv-03125-DEA Patent None District Court, D. New Jersey External link to document
2011-12-21 218 inter alia, infringement of U.S. Patent No. 5,980,882 (“the ‘882 patent”) by Defendants’ submission of …claims of the ‘882 patent. Importantly, and in relevant part, Claim 23 of the patent recites a stability… importance of a prior art patent and noted that if admitted, that patent would defeat plaintiffs’ summary…despite the importance of the patent, hwoever, the court still excluded the patent as untimely. AstraZeneca…made by Reckitt and allegedly covered by the ‘882 patent owned by UCB. For the reasons that follow, the External link to document
2011-12-21 220 inter alia, infringement of U.S. Patent No. 5,980,882 (“the ‘882 patent”) by Defendants’ submission of …released over a period of time. The ‘882 patent, the patent at issue here, claims an “improved” formulation…purposes of patent infringement requires an element-by-element comparison of the patent claim … patented medicine could ever be offered to the public during the life of a patent.” …the ‘882 patent. Here, in an attempt to show that Defendants infringed the ‘882 patent, Plaintiffs External link to document
2010-11-16 75 of the ’882 patent incorporates by reference U.S. Patent 4,221,778 (the “‘778 patent”) which is also… early 1980's. The patent that originally covered it, U.S. Patent 4,221,778, was applied for by…bring this patent infringement action alleging, inter alia, infringement of U.S. Patent No. 5,980,882…herein. I. Overview of the ’882 Patent The ’882 patent, entitled “Drug-Resin Complexes Stabilized… the ’882 patent at issue was applied for in 1997, the same year that the earlier patent covering its External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Dow
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.